UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2021

	ALTO INGREDIENTS, INC.					
	Exact Name of Registrant as Specified in Charter					
Delaware	000-21467	41-2170618				
(State or Other Jurisdiction of Incorporation)	of Incorporation)					
1300 South Second Street Pekin, Illinoi	1300 South Second Street Pekin, Illinois 61554					
(Address of Principal Executive Offices		(Zip Code)				
Registrant	's Telephone Number, Including Area Code: (916)) 403-2123				
(Former	Name or Former Address, if Changed Since Last	Report)				
Check the appropriate box below if the Form 8-K filing is into General Instruction A.2. below):	ended to simultaneously satisfy the filing obligation	ion of the registrant under any of the following provisions (ee				
☐ Written communication pursuant to Rule 425 under the Sec	curities Act (17 CFR 230.425)					
\square Soliciting material pursuant to Rule 14a-12 under the Exch	ange Act (17 CFR 240.14a-12)					
☐ Pre-commencement communications pursuant to Rule 14d-	-2(b) under the Exchange Act (17 CFR 240.14d-2	(b))				
☐ Pre-commencement communication pursuant to Rule 13e-4	4(c) under the Exchange Act (17 CFR 240.13e-4(c	5))				
Securities registered pursuant to Section 12(b) of the Act:						
Title of each class	Trading Symbol(s)	Name of each exchange on which registered				
Common Stock, \$0.001 par value	ALTO	The Nasdaq Stock Market LLC (Nasdaq Capital Market)				
Indicate by check mark whether the registrant is an emerging a Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emergi		ecurities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the				
If an emerging growth company, indicate by check mark if the accounting standards provided pursuant to Section 13(a) of the		nsition period for complying with any new or revised financial				
Item 2.02. Results of Operations and Financial Condition.						
On November 9, 2021, Alto Ingredients, Inc. issued a A copy of the press release is furnished (not filed) as Exhibit 99		tions for the three and nine months ended September 30, 2021. reporated herein by reference.				
Section 18 of the Securities Exchange Act of 1934, as amended this Current Report on Form 8-K is not incorporated by referen	I (the "Exchange Act"), or otherwise subject to the ce into any filings of Alto Ingredients, Inc. made					
Item 9.01. Financial Statements and Exhibits.						
(d) Exhibits.						
Number Description						
rumber Bescription						

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 9, 2021 ALTO INGREDIENTS, INC.

By: /s/ CHRISTOPHER W. WRIGHT

Christopher W. Wright, Vice President, General Counsel & Secretary



Alto Ingredients Reports Third Quarter 2021 Results

- Third Quarter Net Loss of \$3.5 million and Positive Adjusted EBITDA of \$3.0 million
- Subsequent to Quarter-End, the Company Sold its Stockton, CA Facility
- Company is Now Term Debt Free

Sacramento, CA, November 9, 2021 – Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer of specialty alcohols and essential ingredients, reported its financial results for the third quarter ended September 30, 2021.

"In the third quarter we made significant progress in advancing our strategic initiatives, expanding our essential ingredients business and improving our infrastructure," said Mike Kandris, CEO of Alto Ingredients. "We launched an enhanced protein project through the installation of Harvesting Technology's patented CoPromaxTM system at our Magic Valley, Idaho facility. At our Pekin campus, we made significant progress on a number of initiatives. We completed our yeast expansion project and will have our upgraded feed dryers operational by year end. We also finished expanding the capacity of our corn oil production and significantly improved the efficiency and reliability of our Pekin wet mill to further support customer demand long term. We are also working on extending the certifications we obtained at the end of 2020 from our ICP distillery to our Pekin wet mill. We expect to complete this effort by the end of this year and by doing so, provide unique redundancy across the entire Pekin campus and further surety of quality supply to our customers.

"Subsequent to quarter end, on November 8th we announced the sale of our Stockton, California fuel-grade ethanol facility, completing the realignment of our fuel-grade ethanol operations we began 21 months ago. The proceeds from these asset sales were integral to our strategy and contributed to the retirement of approximately \$150 million dollars in term debt over this same period – thus achieving our stated goal to prepay this expensive and restrictive term debt by year end 2021.

"We have completed or are on track to complete this year a number of projects that will increase our annual EBITDA by \$18.5 million starting in 2022. Long-term, we will continue to build on our specialty alcohols and essential ingredients business, focusing our resources on driving profitable growth and progressing our strategic initiatives."



"Net sales were \$306 million, up approximately \$100 million from the prior year's quarter due to an increase in both gallons produced and the average price per gallon sold," stated Bryon McGregor, CFO of Alto Ingredients. "Last year's specialty alcohol sales uniquely benefited from a spike in sanitizer and disinfectant demand from COVID-19. When examining costs and bottom line comparatively, the planned outage of our wet mill, as expected, materially impacted our total revenues and cost of goods sold, driving the gross loss in this year's quarter compared to last year's gross profit.

"Going forward, while we anticipate continued volatility in sanitizer and disinfectant demand over foreseeable future, we expect a more stable, new demand-supply equilibrium will ultimately be achieved as COVID-19 impacts dissipate. We also expect an increase in fixed-price contracted specialty alcohol sales and growing specially alcohol exports. Our upgraded wet mill facility with significantly improved efficiency and reliability will enable us to further support customer demand long term."

Financial Results for the Three Months Ended September 30, 2021 Compared to 2020

- Net sales were \$305.6 million, compared to \$204.7 million.
- Cost of goods sold was \$309.0 million, compared to \$183.8 million.
- Gross loss was \$3.4 million, compared to a gross profit of \$20.9 million.
- Selling, general and administrative expenses were \$5.5 million, compared to \$6.4 million.
- Operating loss was \$8.9 million, compared to operating income of \$26.3 million.
- Net loss available to common stockholders was \$3.5 million, or \$0.05 per share, compared net income of \$14.9 million, or \$0.24 per diluted share.
- Adjusted EBITDA was \$3.0 million, compared to \$34.1 million.
- Cash and cash equivalents were \$36.0 million at September 30, 2021, compared to \$47.7 million at December 31, 2020. On November 8, 2021, the company announced its sale of its fuel-grade ethanol production facility in Stockton, California for \$24.0 million in cash.

Financial Results for the Nine Months Ended September 30, 2021 Compared to 2020

- Net sales were \$822.4 million, compared to \$728.2 million.
- Cost of goods sold was \$796.7 million, compared to \$689.0 million.
- Gross profit was \$25.7 million, compared to \$39.2 million.
- Selling, general and administrative expenses were \$19.8 million, compared to \$25.2 million.

- Operating income was \$2.8 million, compared to \$25.7 million.
- Net income available to common stockholders was \$9.0 million, or \$0.12 per diluted share, compared to \$4.1 million, or \$0.07 per diluted share.
- Adjusted EBITDA was \$33.4 million, compared to \$50.6 million.

2



Third Quarter 2021 Results Conference Call

Management will host a conference call at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on Tuesday, November 9, 2021, and will deliver prepared remarks via webcast followed by a question-and-answer session.

The webcast for the call can be accessed from Alto Ingredients' website at www.altoingredients.com. Alternatively, you may dial the following number up to ten minutes prior to the scheduled conference call time: (877) 847-6066. International callers should dial 00-1 (970) 315-0267. The pass code will be 3778898. If you are unable to participate in the live call, the webcast will be archived for replay on Alto Ingredients' website for one year. In addition, a telephonic replay will be available at 8:00 p.m. Eastern Time on Tuesday, November 9, 2021, through 8:00 p.m. Eastern Time on Tuesday, November 16, 2021. To access the replay, please dial (855) 859-2056. International callers should dial 00-1 (404) 537-3406. The pass code will be 3778898.

Use of Non-GAAP Measures

Management believes that certain financial measures not in accordance with generally accepted accounting principles ("GAAP") are useful measures of operations. The company defines Adjusted EBITDA as unaudited net income (loss) attributed to Alto Ingredients, Inc. before interest expense, interest income, provision (benefit) for income taxes, asset impairments, loss on extinguishment of debt, purchase accounting adjustments, fair value adjustments, and depreciation and amortization expense. A table is provided at the end of this release that provides a reconciliation of Adjusted EBITDA to its most directly comparable GAAP measure, net income (loss) attributed to Alto Ingredients, Inc. Management provides this non-GAAP measure so that investors will have the same financial information that management uses, which may assist investors in properly assessing the company's performance on a period-over-period basis. Adjusted EBITDA is not a measure of financial performance under GAAP and should not be considered as an alternative to net income (loss) attributed to Alto Ingredients, Inc. or any other measure of performance under GAAP, or to cash flows from operating, investing or financing activities as an indicator of cash flows or as a measure of liquidity. Adjusted EBITDA has limitations as an analytical tool and you should not consider this measure in isolation or as a substitute for analysis of the company's results as reported under GAAP.

About Alto Ingredients, Inc.

Alto Ingredients, Inc. (ALTO), formerly known as Pacific Ethanol, Inc., is a leading producer of specialty alcohols and essential ingredients. The company is focused on products for four key markets: Health, Home & Beauty; Food & Beverage; Essential Ingredients; and Renewable Fuels. The company's customers include major food and beverage companies and consumer products companies. For more information please visit www.altoingredients.com.

3



Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements and information contained in this communication that refer to or include Alto Ingredients' estimated or anticipated future results or other non-historical expressions of fact are forward-looking statements that reflect Alto Ingredients' current perspective of existing trends and information as of the date of the communication. Forward looking statements generally will be accompanied by words such as "anticipate," "believe," "plan," "could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible," "potential," "predict," "project," or other similar words, phrases or expressions. Such forward-looking statements include, but are not limited to, statements concerning the timing and effects of Alto Ingredients' strategic initiatives, including its plant improvement projects and extended certifications; the expected effect on annual EBITDA of Alto Ingredients' plant improvement projects; and Alto Ingredients' other plans, objectives, expectations and intentions are not predictions of actual performance. Actual results may differ materially from Alto Ingredients' current expectations depending upon a number of factors affecting Alto Ingredients' business. These factors include, among others, adverse economic and market conditions, including for specialty alcohols and essential ingredients; export conditions and international demand for the company's products; fluctuations in the price of and demand for oil and gasoline; raw material costs, including production input costs, such as corn and natural gas; Alto Ingredients' ability to successfully and timely execute on its plant improvement projects; and the effects – both positive and negative – of the coronavirus pandemic and its resurgence or abatement. These factors also include, among others, the inherent uncertainty associated with financial and other projections; the anticipated size of the markets and continued demand for Alto Ingredients' products; the impact of competitive products and pricing; t

Media Contact

Bryon McGregor, Alto Ingredients, Inc., 916-403-2768, mediarelations@altoingredients.com

Company IR Contact:



ALTO INGREDIENTS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited, in thousands, except per share data)

	Three Months Ended September 30,					nded 60,		
		2021		2020		2021		2020
Net sales	\$	305,556	\$	204,727	\$	822,400	\$	728,205
Cost of goods sold		308,955		183,797		796,729		688,983
Gross profit (loss)		(3,399)		20,930		25,671		39,222
Selling, general and administrative expenses		(5,533)		(6,404)		(19,777)		(25,245)
Asset impairments						(3,100)		<u> </u>
Gain on litigation settlement				11,750				11,750
Income (loss) from operations		(8,932)		26,276		2,794		25,727
Interest expense, net		(429)		(4,199)		(3,359)		(14,153)
Income from loan forgiveness		5,973				9,860		-
Fair value adjustments		_		(6,856)				(7,497)
Other income (expense), net		256		(6)	_	641	_	(1,164)
Income (loss) before benefit for income taxes		(3,132)		15,215		9,936		2,913
Benefit for income taxes			_		_		_	
Consolidated net income (loss)		(3,132)		15,215		9,936		2,913
Net loss attributed to noncontrolling interests			_		_		_	2,166
Net income (loss) attributed to Alto Ingredients, Inc.	\$	(3,132)	\$	15,215	\$	9,936	\$	5,079
Preferred stock dividends	\$	(319)	\$	(319)	\$	(946)	\$	(949)
Net income (loss) available to common stockholders	\$	(3,451)	\$	14,896	\$	8,990	\$	4,130
Net income (loss) per share, basic	\$	(0.05)	\$	0.25	\$	0.13	\$	0.07
Net income (loss) per share, diluted	\$	(0.05)	\$	0.24	\$	0.12	\$	0.07
Weighted-average shares outstanding, basic		71,383		58,503		71,002		55,620
Weighted-average shares outstanding, diluted		71,383		61,699		72,260		57,958

5



ALTO INGREDIENTS, INC. CONSOLIDATED BALANCE SHEETS (unaudited, in thousands, except par value)

	September 30,		ember 31,
ASSETS	2021		2020
Current Assets:			
Cash and cash equivalents	\$	36,029	\$ 47,667
Accounts receivable, net		78,424	43,491
Inventories		58,117	37,925
Prepaid inventory		5,480	891
Derivative instruments		12,977	17,149
Assets held-for-sale		30,158	58,295
Other current assets		5,413	8,628
Total current assets		226,598	214,046
Property and equipment, net		224,319	229,486
Other Assets:		_	
Right of use operating lease assets, net		12,715	11,046

Notes receivable	12,423	14,337
Intangible assets	2,678	2,678
Other assets	4,671	5,225
Total other assets	32,487	33,286
Total Assets	\$ 483,404	\$ 476,818

6



ALTO INGREDIENTS, INC. CONSOLIDATED BALANCE SHEETS (CONTINUED) (unaudited, in thousands, except par value)

Current Liabilities \$28,387 \$13,047 Accounts payable – trade \$28,387 \$13,010 Accruent portion – operating leases 3,216 2,180 Current portion – long-term debt 17,687 25,533 Derivative instruments 2,735 — Liabilities held-for-sale 10,500 19,542 Other current liabilities 6,468 15,524 Total current portion 70,621 71,807 Operating leases, net of current portion 70,621 71,807 Operating leases, net of current portion 9,365 8,715 Other liabilities 13,774 13,134 Total Liabilities 178,208 180,383 Stockholders' Equity: Preferred stock, 50,001 par value; 10,000 shares authorized; Series Series 2: 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Series B: 927 shares issued and outstanding as of September 30, 2021 and December 31, 2020 73 72 Common stock, 50,001 par value; 30,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 <	LIABILITIES AND STOCKHOLDERS' EQUITY	September 30, 2021		Dec	2020
Accrued Liabilities	Current Liabilities:				
Current portion – operating leases 3,216 2,180 Current portion – long-term debt 17,687 25,533 Derivative instruments 2,735 — Liabilities held-for-sale 10,500 19,542 Other current liabilities 6,468 15,524 Total current liabilities 84,448 86,927 Long-term debt, net of current portion 70,621 71,807 Operating leases, net of current portion 9,365 8,715 Other liabilities 13,774 13,134 Total Liabilities 13,774 13,134 Total Liabilities 178,208 180,583 Stockholders' Equity: Preferred stock, \$0.001 par value; 10,000 shares authorized; Series A: 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 1 1 1 Common stock, \$0.001 par value; 30,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0.001 par value; 3,000,000 shares authorized; 1 share issued and outstanding as of September 30, 2021 a	Accounts payable – trade	\$	28,387	\$	13,047
Current portion – long-term debt			,		
Derivative instruments			/		/
Liabilities held-for-sale 10,500 19,542 Other current liabilities 6,468 15,524 Total current liabilities 84,448 86,927 Long-term debt, net of current portion 70,621 71,807 Operating leases, net of current portion 9,365 8,715 Other liabilities 13,774 13,134 Total Liabilities 178,208 180,583 Stockholders' Equity: Preferred stock, \$0,001 par value; 10,000 shares authorized; Series A: 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Series B: 927 shares issued and outstanding as of September 30, 2021 and December 31, 2020 1 1 1 1 Common stock, \$0,001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0,001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 73 72 Additional paid-in capital 1,036,608 1,036,638 1,036,638 Accumulated other comprehensive loss (3,878) (3,878)			,		25,533
Other current liabilities 6,468 15,524 Total current liabilities 84,448 86,927 Long-term debt, net of current portion 70,621 71,807 Operating leases, net of current portion 9,365 8,715 Other liabilities 13,774 13,134 Total Liabilities 178,208 180,583 Stockholders' Equity: Preferred stock, \$0,001 par value; 10,000 shares authorized; Series A: 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Series B: 927 shares issued and outstanding as of September 30, 2021 and December 31, 2020 1 1 1 1 Common stock, \$0,001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0,001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Additional paid-in capital 1,036,608 1,036,608 1,036,608 1,036,608 1,036,608 1,036,608 1,036,608			/		_
Total current liabilities 84,448 86,927 Long-term debt, net of current portion 70,621 71,807 Operating leases, net of current portion 9,365 8,715 Other liabilities 13,744 13,134 Total Liabilities 13,744 13,134 Total Liabilities 178,000 par value; 10,000 shares authorized; Series A: 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Series B: 927 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 31, 2020 Additional paid-in capital 1,000,000 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 Additional paid-in capital 1,000,000 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 Additional paid-in capital 1,000,000 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 Accumulated other comprehensive loss (3,878) 4,3878) Accumulated other comprehensive loss (3,878) 4,36,588 Accumulated step (727,608) (736,598) Total Stockholders' Equity 305,000 par value; 3,05,000 par value; 3,000 par val			10,500		19,542
Long-term debt, net of current portion 70,621 71,807 Operating leases, net of current portion 9,365 8,715 Other liabilities 13,774 13,134 Total Liabilities 178,208 180,583 Stockholders' Equity: Alto Ingredients, Inc. Stockholders' Equity: Preferred stock, \$0.001 par value; 10,000 shares authorized; Series A: 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Series B: 927 shares issued and outstanding as of September 30, 2021 and December 31, 2020 1 1 Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 73 72 Additional paid-in capital 1,036,608 1,036,608 1,036,608 1,036,608 1,036,608 1,036,608 1,036,980 1,036,980 1,036,980 1,036,980 1,036,980 1,036,980 1,036,980 1,036,980	Other current liabilities		6,468		15,524
Operating leases, net of current portion 9,365 8,715 Other liabilities 13,774 13,134 Total Liabilities 178,208 180,583 Stockholders' Equity: Preferred stock, \$0,001 par value; 10,000 shares authorized; Series A: 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Series B: 927 shares issued and outstanding as of September 30, 2021 and December 31, 2020 1 1 September 30, 2021 and December 31, 2020 1 1 Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 73 72 Additional paid-in capital 1,036,608 1,036,638 Accumulated other comprehensive loss (3,878) 3,878 Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235	Total current liabilities		84,448		86,927
Operating leases, net of current portion 9,365 8,715 Other liabilities 13,774 13,134 Total Liabilities 178,208 180,583 Stockholders' Equity: Preferred stock, \$0,001 par value; 10,000 shares authorized; Series A: 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Series B: 927 shares issued and outstanding as of September 30, 2021 and December 31, 2020 1 1 September 30, 2021 and December 31, 2020 1 1 Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 73 72 Additional paid-in capital 1,036,608 1,036,638 Accumulated other comprehensive loss (3,878) 3,878 Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235					
Other liabilities 13,774 13,134 Total Liabilities 178,208 180,583 Stockholders' Equity: Alto Ingredients, Inc. Stockholders' Equity: Preferred stock, \$0.001 par value; 10,000 shares authorized; Series A: 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Series B: 927 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 — — Additional paid-in capital 1,036,608 1,036,638 Accumulated other comprehensive loss (3,878) (3,878) Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235	Long-term debt, net of current portion		70,621		71,807
Total Liabilities 178,208 180,583 Stockholders' Equity: Alto Ingredients, Inc. Stockholders' Equity: Preferred stock, \$0.001 par value; 10,000 shares authorized; Series A: 0 shares issued and outstanding as of Series B: 927 shares issued and outstanding as of September 30, 2021 and December 31, 2020 September 30, 2021 and December 31, 2020 Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 — — — Additional paid-in capital 1,036,608 1,036,638 Accumulated other comprehensive loss (3,878) (3,878) Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235	Operating leases, net of current portion		9,365		8,715
Stockholders' Equity: Alto Ingredients, Inc. Stockholders' Equity: Preferred stock, \$0.001 par value; 10,000 shares authorized; Series A: 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Series B: 927 shares issued and outstanding as of September 30, 2021 and December 31, 2020 1 Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 — — Additional paid-in capital 1,036,608 1,036,638 Accumulated other comprehensive loss (3,878) (3,878) Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235	Other liabilities		13,774		13,134
Stockholders' Equity: Alto Ingredients, Inc. Stockholders' Equity: Preferred stock, \$0.001 par value; 10,000 shares authorized; Series A: 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Series B: 927 shares issued and outstanding as of September 30, 2021 and December 31, 2020 1 Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 — — Additional paid-in capital 1,036,608 1,036,638 Accumulated other comprehensive loss (3,878) (3,878) Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235	Total Liabilities		178,208		180,583
Alto Ingredients, Inc. Stockholders' Equity: Preferred stock, \$0.001 par value; 10,000 shares authorized; Series A: 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Series B: 927 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Total Stockholders' Equity Authorized: 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					
Alto Ingredients, Inc. Stockholders' Equity: Preferred stock, \$0.001 par value; 10,000 shares authorized; Series A: 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Series B: 927 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Total Stockholders' Equity Authorized: 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Stockholders' Equity:				
Preferred stock, \$0.001 par value; 10,000 shares authorized; Series A: 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 September 30, 2021 and December 31, 2020 Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 Additional paid-in capital 1,036,608 1,036,638 Accumulated other comprehensive loss (3,878) (3,878) Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235					
Series A: 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020 Series B: 927 shares issued and outstanding as of 1 September 30, 2021 and December 31, 2020 1 Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 — — Additional paid-in capital 1,036,608 1,036,638 Accumulated other comprehensive loss (3,878) (3,878) Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235					
Series B: 927 shares issued and outstanding as of September 30, 2021 and December 31, 2020 1 1 Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 — — — Additional paid-in capital 1,036,608 1,036,638 Accumulated other comprehensive loss (3,878) (3,878) Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235					
September 30, 2021 and December 31, 2020 1 1 Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 — — — Additional paid-in capital 1,036,608 1,036,638 Accumulated other comprehensive loss (3,878) (3,878) Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235	September 30, 2021 and December 31, 2020				
Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 — — — Additional paid-in capital 1,036,608 1,036,638 Accumulated other comprehensive loss (3,878) (3,878) Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235	Series B: 927 shares issued and outstanding as of				
2021 and December 31, 2020, respectively 73 72 Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 — — Additional paid-in capital 1,036,608 1,036,638 Accumulated other comprehensive loss (3,878) (3,878) Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235	September 30, 2021 and December 31, 2020		1		1
Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and December 31, 2020 Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Total Stockholders' Equity 1,036,608 1,036,638 (3,878) (3,878) (727,608) (736,598) 7 otal Stockholders' Equity	Common stock, \$0.001 par value; 300,000 shares authorized; 72,800 and 72,487 shares issued and outstanding as of September 30,				
December 31, 2020 — Additional paid-in capital 1,036,608 1,036,638 Accumulated other comprehensive loss (3,878) (3,878) Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235	2021 and December 31, 2020, respectively		73		72
Additional paid-in capital 1,036,608 1,036,638 Accumulated other comprehensive loss (3,878) (3,878) Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235	Non-voting common stock, \$0.001 par value; 3,553 shares authorized; 1 share issued and outstanding as of September 30, 2021 and				
Accumulated other comprehensive loss (3,878) (3,878) Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235	December 31, 2020		_		_
Accumulated deficit (727,608) (736,598) Total Stockholders' Equity 305,196 296,235	Additional paid-in capital		1,036,608		1,036,638
Total Stockholders' Equity 305,196 296,235	Accumulated other comprehensive loss		(3,878)		(3,878)
The 171 1884 - 100 11 11 17 16	Accumulated deficit		(727,608)		(736,598)
The 171 1884 - 100 11 11 17 16	Total Stockholders' Equity		305,196		
\$ 403,404 \$ 470,616		9		\$	
	**** * ****	φ	705,704	Ψ	770,010

7



Reconciliation of Adjusted EBITDA to Net Income (Loss)

	 Three Months Ended September 30,					Nine Months Ended September 30,				
(in thousands) (unaudited)	 2021 2020			2021		2020				
Net income (loss) attributed to Alto Ingredients, Inc.	\$ (3,132)	\$	15,215	\$	9,936	\$	5,079			
Adjustments:										
Interest expense	429		4,199		3,359		14,153			
Interest income	(183)		(196)		(553)		(368)			
Asset impairments	_		_		3,100		_			
Fair value adjustments	_		6,856		_		7,497			
Benefit for income taxes	_		_		_		_			

Depreciation and amortization expense*	 5,851	8,049	 17,520	 24,254
Total adjustments	6,097	18,908	23,426	45,536
Adjusted EBITDA	\$ 2,965	\$ 34,123	\$ 33,362	\$ 50,615

^{*} Adjusted for noncontrolling interests.

8



Commodity Price Performance

	Three Months Ended September 30,				Nine Months Ended September 30,			
(unaudited)		2021		2020	2021		2020	
Fuel-grade ethanol production gallons sold (in millions)		38.3		21.9	118.6		148.0	
Specialty alcohol production gallons sold (in millions)		19.7		21.6	63.1		74.9	
Third party fuel-grade ethanol gallons sold (in millions)		67.2		76.7	180.5		213.0	
Total gallons sold (in millions)		125.2		120.2	362.2		435.9	
Total gallons produced (in millions)		60.6		45.2	182.2		209.1	
Production capacity utilization		59%)	40%	57%		54%	
Average sales price per gallon	\$	2.47	\$	1.71	\$ 2.27	\$	1.60	
Average CBOT ethanol price per gallon	\$	2.25	\$	1.27	\$ 2.08	\$	1.20	
Corn cost – CBOT equivalent	\$	6.09	\$	3.29	\$ 5.71	\$	3.49	
Average basis		0.89		0.22	0.53		0.29	
Delivered cost of corn	\$	6.98	\$	3.51	\$ 6.24	\$	3.78	
Total essential ingredients tons sold (in thousands)		305.6		255.5	886.5		1,177.5	
Co-product return % (1)		29.5%)	50.2%	33.8%		44.6%	

⁽¹⁾ Co-product revenue as a percentage of delivered cost of corn.

9



Segment Financials

		Three Months Ended September 30,					ths En	
		2021		2020		2021		2020
Net Sales								
Marketing and distribution:								
Alcohol sales, gross	\$	112,391	\$	84,001	\$	255,702	\$	212,625
Alcohol sales, net		505		382		1,489		1,117
Intersegment sales		2,415		1,598		7,277		7,751
Total marketing and distribution sales	<u>'</u>	115,311		85,981		264,468		221,493
Pekin Campus production, recorded as gross:								
Alcohol sales	\$	114,587	\$	77,075	\$	341,967	\$	255,737
Essential ingredient sales		46,016		27,619		140,670		101,123
Intersegment sales		293		197		920		877
Total Pekin Campus sales		160,896		104,891		483,557		357,737
r		,		. ,		,		
Other production, recorded as gross:								
Alcohol sales	\$	25,190	\$	11,765	\$	63,311	\$	120,797
Essential ingredient sales		6,867		3,885		19,261		36,806
Intersegment sales		259		420		896		1,121
Total Other production sales		32,316		16,070		83,468		158,724
1		,		.,		, , , ,		- 7.
Intersegment eliminations		(2,967)		(2,215)		(9,093)		(9,749)
č		,,,,,			_	(-)/	_	(*) * - /

Net sales as reported	\$ 305,556	\$ 204,727	\$ 822,400	\$ 728,205
Cost of goods sold:				
Marketing and distribution	\$ 105,902	\$ 84,589	\$ 245,606	\$ 210,827
Pekin Campus production	169,721	80,280	468,972	302,120
Other production	35,613	20,718	87,055	181,382
Intersegment eliminations	(2,281)	(1,790)	(4,904)	(5,346)
Cost of goods sold as reported	\$ 308,955	\$ 183,797	\$ 796,729	\$ 688,983
Gross profit (loss):				
Marketing and distribution	\$ 9,409	\$ 1,392	\$ 18,862	\$ 10,666
Pekin Campus production	(8,825)	24,611	14,585	55,617
Other production	(3,297)	(4,648)	(3,587)	(22,658)
Intersegment eliminations	 (686)	(425)	 (4,189)	 (4,403)
Gross profit (loss)	\$ (3,399)	\$ 20,930	\$ 25,671	\$ 39,222